Therapeutic Compounds for Glaucoma via Metabolic Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly those involving eicosanoids and their derivatives, face limitations in effectively managing elevated intraocular pressure and ocular hypertensive conditions, as they may not adequately address the underlying causes of intraocular pressure obstruction and have limitations in metabolic stability and efficacy.
Innovation Solution
Development of specific compounds with structural formulas that include organic acid functional groups, amides, esters, or tetrazolyl functional groups, which act as bioisosteres for carboxylic acids, to enhance metabolic stability and efficacy in reducing intraocular pressure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If eicosanoids and their derivatives are used for treating glaucoma, then intraocular pressure can be reduced, but metabolic stability and efficacy are limited
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of eicosanoid derivatives through systematic variations in the R1, R2, R3, R4, and R5 substituents. These structural parameter changes enhance metabolic stability while maintaining the ability to reduce intraocular pressure, resolving the contradiction between efficacy and stability.
Solution Approach 2:
The patent employs composite material principles by creating complex molecular structures that combine multiple functional groups and substituents on the prostanoic acid skeleton. These composite structures integrate properties that simultaneously improve metabolic stability and therapeutic efficacy for glaucoma treatment.
2Reliability
If current eicosanoid treatments are used, then ocular hypertensive conditions can be managed, but underlying causes of intraocular pressure obstruction are not adequately addressed
Solution Approach 1:
The patent applies the extraction principle by isolating and optimizing specific structural elements of eicosanoids that directly target the mechanisms of aqueous humor outflow obstruction. By extracting and enhancing these key functional components through systematic structural modification, the compounds more effectively address the underlying causes of intraocular pressure obstruction rather than merely managing symptoms.
Data Source
AI summary
Disclosed herein is a compound of the formula. Therapeutic methods, compositions, and medicaments for the treatment of glaucoma or ocular hypertension related thereto are also disclosed.